Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SVRA Savara Inc

Not Yet Opened 11-25 16:00:00 EST

3.41

+0.05

+1.49%

盘后3.32

-0.09-2.58%

18:57 EST

High3.49	Low3.37	Vol908.69K
Open3.37	D1 Closing3.36	Amplitude3.57%
Mkt Cap585.22M	Tradable Cap382.59M	Total Shares171.62M
T/O3.10M	T/O Rate0.81%	Tradable Shares112.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SVRA","market":"US","secType":"STK","nameCN":"Savara Inc","latestPrice":3.41,"timestamp":1732568400000,"preClose":3.36,"halted":0,"volume":908687,"hourTrading":{"tag":"盘后","latestPrice":3.3219,"preClose":3.41,"latestTime":"18:57 EST","volume":43650,"amount":148806.9299,"timestamp":1732579067908},"delay":0,"floatShares":112196279,"shares":171618944,"eps":-0.425487,"marketStatus":"Not Yet Opened","change":0.05,"latestTime":"11-25 16:00:00 EST","open":3.37,"high":3.49,"low":3.37,"amount":3104605.2834706004,"amplitude":0.035714,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.425487,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732611600000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.36,"preHourTrading":{"tag":"盘前","latestPrice":3.505,"preClose":3.36,"latestTime":"09:24 EST","volume":94,"amount":315.865004,"timestamp":1732544667301},"postHourTrading":{"tag":"盘后","latestPrice":3.3219,"preClose":3.41,"latestTime":"18:57 EST","volume":43650,"amount":148806.9299,"timestamp":1732579067908},"volumeRatio":0.308726,"impliedVol":0.7003,"impliedVolPercentile":0.4524},"requestUrl":"/m/hq/s/SVRA/tweets","defaultTab":"tweets","newsList":[{"id":"2485890214","title":"Savara Announces New Employment Inducement Grant","url":"https://stock-news.laohu8.com/highlight/detail?id=2485890214","media":"Business Wire","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485890214?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:05","pubTimestamp":1732309500,"startTime":"0","endTime":"0","summary":"LANGHORNE, Pa., November 22, 2024----Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees.On November 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 80,000 shares of the Company’s common stock and restricted stock units  covering an aggregate of 70,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635 of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SQxpFOkTqEha3yLTkr6olA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f5fd24ccdfc385687a9b19729c0e9901","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SQxpFOkTqEha3yLTkr6olA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f5fd24ccdfc385687a9b19729c0e9901"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-employment-inducement-grant-210500143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","QID","TQQQ","MNQmain","PSQ","NQmain","SQQQ",".IXIC","SVRA","BK4139"],"gpt_icon":1},{"id":"2485263865","title":"BRIEF-Savara Announces Encore Presentation Of Results From The Phase 3 Impala-2 Trial Of Molgramostim Inhalation Solution (Molgramostim) In Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) At The British Thoracic Society Winter Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485263865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485263865?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:36","pubTimestamp":1732282613,"startTime":"0","endTime":"0","summary":"BRIEF-Savara Announces Encore Presentation Of Results From The Phase 3 Impala-2 Trial Of Molgramostim Inhalation Solution (Molgramostim) In Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nTUA2PPCPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2485250364","title":"Savara Announces Encore Presentation of Results From the Phase 3 Impala-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the British Thoracic Society Winter Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485250364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485250364?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:05","pubTimestamp":1732280700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nTUA2PPCPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2485250136","title":"Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485250136","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485250136?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:05","pubTimestamp":1732280700,"startTime":"0","endTime":"0","summary":"LANGHORNE, Pa., November 22, 2024----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from the pivotal, Phase 3 IMPALA-2 trial will be presented at the British Thoracic Society  Winter Meeting, taking place November 27-29, 2024, in London, England.About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution , is a recombinant human granulocyte-macrophage colony-stimulating factor  in Phase 3 development for autoimmune pulmonary alveolar proteinosis . Molgramostim is delivered via an investigational eFlow Nebulizer System  specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More informa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vF9H6VvKk8gOMnTen3ZuBQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a5c0f506c1f293b824bb9ee664d4ee81","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vF9H6VvKk8gOMnTen3ZuBQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a5c0f506c1f293b824bb9ee664d4ee81"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-encore-presentation-results-130500452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2483560728","title":"Savara Shares Fall After Evercore ISI Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2483560728","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483560728?lang=en_us&edition=fundamental","pubTime":"2024-11-14 03:19","pubTimestamp":1731525549,"startTime":"0","endTime":"0","summary":"Savara  shares were down over 14% in recent Wednesday trading after Evercore ISI downgraded the company's stock to in line from outperform and cut its price target to $5 from $7.Trading volume stood at about 2.3 million shares against a daily average of roughly 1.2 million.Price: 3.29, Change: -0.54, Percent Change: -14.18","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SVRA"],"gpt_icon":0},{"id":"2483853880","title":"Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483853880","media":"GuruFocus.com","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483853880?lang=en_us&edition=fundamental","pubTime":"2024-11-14 02:21","pubTimestamp":1731522086,"startTime":"0","endTime":"0","summary":"Evercore ISI downgraded Savara  to \"in line\" from \"outperform,\" citing worries over Molbreevi's FDA approval.The downgrading highlights possible obstacles in Savara's strategy to bring the medication to market resulting from doubts about the company's manufacturing capacity.Evercore also lowered Savara's price target to $5 from $7; SVRA stock is down 9.5% to open Wednesday's trading at $3.45. Analyst Liisa Bayko clarified that although Savara wants to finish its rolling Biologics License Application for Molbreevi by the end of the first quarter in 2025, its current manufacturing approach may hinder FDA clearance path. Should accepted with a priority evaluation, Molbreevi might enter the market by the end of 2025, possibly bringing in more than $500 million yearly, Bayko said.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/slb6hco9s4qvtSd.Xyb6oQ--~B/aD0zNjQ4O3c9NTQ3MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/ac90e83fbe2c24857411d69cfbec7675","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/slb6hco9s4qvtSd.Xyb6oQ--~B/aD0zNjQ4O3c9NTQ3MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/ac90e83fbe2c24857411d69cfbec7675"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/evercore-downgrades-savara-manufacturing-concerns-182126627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SVRA"],"gpt_icon":0},{"id":"2483884981","title":"Savara Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483884981","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483884981?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:53","pubTimestamp":1731509580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SVRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 09:53 ET (14:53 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA"],"gpt_icon":0},{"id":"2483785889","title":"Evercore ISI Downgrades Savara to In Line From Outperform, Adjusts Price Target to $5 From $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2483785889","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483785889?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:06","pubTimestamp":1731503191,"startTime":"0","endTime":"0","summary":"Evercore ISI Downgrades Savara to In Line From Outperform, Adjusts Price Target to $5 From $7","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SVRA"],"gpt_icon":0},{"id":"2483000473","title":"Savara Announces Participation in Upcoming Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2483000473","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483000473?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:05","pubTimestamp":1731503100,"startTime":"0","endTime":"0","summary":"LANGHORNE, Pa., November 13, 2024----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending the below listed upcoming healthcare conferences and participating in fireside chats.Jefferies London Healthcare Conference, November 19-21, 2024Fireside Chat: November 20th, 1:00pm GT/8:00am ET/5:00am PT. Piper Sandler 36th Annual Healthcare Conference, December 3-5, 2024Fireside Chat: December 3rd, 8:30am ET/5:30am PT. *MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution.Media and Investor Relations Contact Savara Inc.Temre Johnson, Executive Director, Corporate Affairsir@savarapharma.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5VH9t4y.N6VaRwrQVEUalA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/605644126191325ff02841b3c85bbce0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5VH9t4y.N6VaRwrQVEUalA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/605644126191325ff02841b3c85bbce0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-participation-upcoming-healthcare-130500395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4137","SVRA","HCSG"],"gpt_icon":0},{"id":"2483268006","title":"Savara Cut to In-Line From Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2483268006","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483268006?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:10","pubTimestamp":1731499800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SVRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 07:10 ET (12:10 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA"],"gpt_icon":0},{"id":"2482846180","title":"Savara Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2482846180","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482846180?lang=en_us&edition=fundamental","pubTime":"2024-11-12 23:27","pubTimestamp":1731425221,"startTime":"0","endTime":"0","summary":"* Savara Inc    reported a quarterly adjusted loss of 11 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -10 cents.  The mea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA"],"gpt_icon":0},{"id":"2482870453","title":"Savara Q3 EPS $(0.11), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2482870453","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482870453?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:22","pubTimestamp":1731417725,"startTime":"0","endTime":"0","summary":"Savara (NASDAQ:SVRA) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 10 percent decrease over losses of $(0.10) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41899712/savara-q3-eps-0-11-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Savara Q3 EPS $(0.11), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA"],"gpt_icon":0},{"id":"2482030702","title":"Savara Inc: Sufficiently Capitalized Through 2Q 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2482030702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482030702?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:05","pubTimestamp":1731416700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nTUA9HPYCL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2482020457","title":"Savara Inc: Updates Guidance on Molbreevi Bla Submission Completion Date to End of 1Q 2025 From 1H 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2482020457","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482020457?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:05","pubTimestamp":1731416700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nTUA9HPYCL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2482088395","title":"Savara Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482088395","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482088395?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:05","pubTimestamp":1731416700,"startTime":"0","endTime":"0","summary":"Recently Completed Pre-BLA Meeting with FDA for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis . Company Plans to Initiate Biologics License Application  Rolling Submission by End of Year. With ~$219M in Cash and Short-Term Investments, the Company Believes it is Sufficiently Capitalized through 2Q 2027. LANGHORNE, Pa., November 12, 2024----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2024 and provided a business update.Savara's net loss for the third quarter of 2024 was $24.2 million, or $ per share, compared with a net loss of $16.6 million, or $ per share, for the third quarter of 2023.General and administrative expenses increased by $1.9 million, or 45.0%, to $6.0 million for the three months ended September 30, 2024 from $4","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oPE5lOx1p22d3Opl38N3zg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0d2ac8a61f534f5f44758b269c852276","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oPE5lOx1p22d3Opl38N3zg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0d2ac8a61f534f5f44758b269c852276"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-reports-third-quarter-2024-130500652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MAA","BK4588","BK4215","SVRA","BK4139","BK4585"],"gpt_icon":0},{"id":"2481555700","title":"Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2481555700","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481555700?lang=en_us&edition=fundamental","pubTime":"2024-11-05 05:05","pubTimestamp":1730754300,"startTime":"0","endTime":"0","summary":"About Savara. Contacts","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QCeWA5ynsmcRoF1gB_TWGA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/af02b131bb0f78ed05991fab9a740394","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QCeWA5ynsmcRoF1gB_TWGA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/af02b131bb0f78ed05991fab9a740394"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-present-guggenheim-inaugural-healthcare-210500663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCSG","BK4137","SVRA","BK4139"],"gpt_icon":0},{"id":"2477357293","title":"Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of \"The Balancing Act®\" Airing on Lifetime® TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2477357293","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477357293?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:05","pubTimestamp":1729598700,"startTime":"0","endTime":"0","summary":"LANGHORNE, Pa., October 22, 2024----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that a new episode of The Balancing Act, sponsored by Savara and featuring autoimmune Pulmonary Alveolar Proteinosis , is airing on Lifetime TV’s Behind the Mystery a recurring series on The Balancing Act television show devoted to advocating for people with rare and genetic diseases. The episode centers on the diagnostic journey of an aPAP patient and includes insights from Bruce Trapnell, M.D., Professor of Medicine and Pediatrics, University of Cincinnati College of Medicine and the International Coordinating Investigator for Savara’s IMPALA-2 Phase 3 clinical trial of molgramostim inhalation solution  in aPAP.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/iBBp3kt_.ovw8E9NcTVzSg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8f529693864926c8494cfd57963711af","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/iBBp3kt_.ovw8E9NcTVzSg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8f529693864926c8494cfd57963711af"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-rare-lung-disease-120500648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4100","BK4180","BK4139","TV","LCUT","SVRA"],"gpt_icon":0},{"id":"2476216796","title":"Savara Announces New Employment Inducement Grant","url":"https://stock-news.laohu8.com/highlight/detail?id=2476216796","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476216796?lang=en_us&edition=fundamental","pubTime":"2024-10-19 04:05","pubTimestamp":1729281900,"startTime":"0","endTime":"0","summary":"LANGHORNE, Pa., October 18, 2024----Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees.On October 17, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 95,000 shares of the Company’s common stock and restricted stock units  covering an aggregate of 95,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635 of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/o1o04aTLm.B6s.SX9OkQdg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/70152155c94fed54680071dc794b6edf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/o1o04aTLm.B6s.SX9OkQdg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/70152155c94fed54680071dc794b6edf"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-employment-inducement-grant-200500748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QID","QLD","SVRA","MNQmain","NQmain","SQQQ","BK4139",".IXIC","PSQ","TQQQ"],"gpt_icon":1},{"id":"2473406674","title":"Savara Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2473406674","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473406674?lang=en_us&edition=fundamental","pubTime":"2024-10-08 18:59","pubTimestamp":1728385140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SVRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 08, 2024 06:59 ET (10:59 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA"],"gpt_icon":0},{"id":"2472327640","title":"Evercore ISI Remains a Buy on Savara (SVRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2472327640","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472327640?lang=en_us&edition=fundamental","pubTime":"2024-10-01 20:35","pubTimestamp":1727786144,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Liisa Bayko maintained a Buy rating on Savara (SVRA – Research Report) today and set a price target of $7.00. The company’s sh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-remains-a-buy-on-savara-svra-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-remains-a-buy-on-savara-svra-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SVRA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.savarapharma.com;www.masttherapeutics.com","stockEarnings":[{"period":"1week","weight":0.152},{"period":"1month","weight":-0.0201},{"period":"3month","weight":-0.2106},{"period":"6month","weight":-0.1783},{"period":"1year","weight":-0.1026},{"period":"ytd","weight":-0.2745}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.143235},{"month":2,"riseRate":0.272727,"avgChangeRate":-0.048875},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.022561},{"month":4,"riseRate":0.583333,"avgChangeRate":0.025179},{"month":5,"riseRate":0.75,"avgChangeRate":0.049473},{"month":6,"riseRate":0.5,"avgChangeRate":-0.036588},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.037047},{"month":8,"riseRate":0.5,"avgChangeRate":-0.004589},{"month":9,"riseRate":0.5,"avgChangeRate":0.004673},{"month":10,"riseRate":0.083333,"avgChangeRate":-0.1617},{"month":11,"riseRate":0.5,"avgChangeRate":0.100508},{"month":12,"riseRate":0.636364,"avgChangeRate":0.271403}],"exchange":"NASDAQ","name":"Savara Inc","nameEN":"Savara Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Savara Inc(SVRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Savara Inc,SVRA,Savara Inc股票,Savara Inc股票老虎,Savara Inc股票老虎国际,Savara Inc行情,Savara Inc股票行情,Savara Inc股价,Savara Inc股市,Savara Inc股票价格,Savara Inc股票交易,Savara Inc股票购买,Savara Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Savara Inc(SVRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction